Trials / Terminated
TerminatedNCT00917826
Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
A Phase II Trial of Low-Dose Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+)Lymphoid Malignancies
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- HemaQuest Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess whether administration of Arginine Butyrate + ganciclovir/valganciclovir for up to three 21-day cycles is tolerable, and results in partial or complete responses in patients with EBV(+) lymphoid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arginine Butyrate | 1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle) |
| DRUG | Ganciclovir | 5 mg/kg administered IV over 1 hour (Days 1-5 of each 21 day cycle) |
| DRUG | Valganciclovir | 900 mg BID for 16 days (Days 6-21 of each 21 day cycle) |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2009-09-01
- First posted
- 2009-06-10
- Last updated
- 2011-08-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00917826. Inclusion in this directory is not an endorsement.